BioMarin wants USITC exclusion order against Ascendis, Wacker
MLex Summary: BioMarin Pharmaceutical accused European rivals Ascendis Pharma and Wacker Biotech of importing illegal quantities of patented C-type natriuretic peptide (CNP) compounds in a US International Trade Commission complaint, in...To view the full article, register now.
Already a subscriber? Click here to view full article